Evelo Biosciences Inc.

9.37-0.6000-6.02%Vol 258.46K1Y Perf 124.76%
Jul 23rd, 2021 16:00 DELAYED
BID9.36 ASK9.38
Open9.87 Previous Close9.97
Pre-Market- After-Market-
 - -  - -%
Target Price
22.40 
Analyst Rating
Moderate Buy 2.50
Potential %
139.06 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/82 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/69 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/68 
Income Ranking
 —    -
Market Cap500.11M 
Earnings Rating
Sell
Price Range Ratio 52W %
35.14 
Earnings Date
29th Jul 2021

Today's Price Range

9.289.92

52W Range

3.6519.93

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-17.44%
1 Month
-37.66%
3 Months
-18.80%
6 Months
-40.36%
1 Year
124.76%
3 Years
-31.61%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
EVLO9.37-0.6000-6.02
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.53-0.55-3.77
Q04 2020-0.48-0.62-29.17
Q03 2020-0.50-0.4510.00
Q02 2020-0.71-0.6311.27
Q01 2020-0.71-0.710.00
Q04 2019-0.65-0.70-7.69
Q03 2019-0.67-0.670.00
Q02 2019-0.65-0.650.00
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.55-3.77Negative
9/2021 QR-0.56-3.70Negative
12/2021 FY-2.20-5.77Negative
12/2022 FY-1.97-4.23Negative
Next Report Date29th Jul 2021
Estimated EPS Next Report-0.54
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume258.46K
Shares Outstanding53.37M
Trades Count3.37K
Dollar Volume2.18M
Avg. Volume233.38K
Avg. Weekly Volume389.75K
Avg. Monthly Volume287.18K
Avg. Quarterly Volume190.84K

Evelo Biosciences Inc. (NASDAQ: EVLO) stock closed at 9.37 per share at the end of the most recent trading day (a -6.02% change compared to the prior day closing price) with a volume of 258.47K shares and market capitalization of 500.11M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 98 people. Evelo Biosciences Inc. CEO is Balkrishan Gill.

The one-year performance of Evelo Biosciences Inc. stock is 124.76%, while year-to-date (YTD) performance is -22.5%. EVLO stock has a five-year performance of %. Its 52-week range is between 3.65 and 19.93, which gives EVLO stock a 52-week price range ratio of 35.14%

Evelo Biosciences Inc. currently has a PE ratio of -5.00, a price-to-book (PB) ratio of 6.90, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -83.68%, a ROC of -98.07% and a ROE of -155.40%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Evelo Biosciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.54 for the next earnings report. Evelo Biosciences Inc.’s next earnings report date is 29th Jul 2021.

The consensus rating of Wall Street analysts for Evelo Biosciences Inc. is Moderate Buy (2.5), with a target price of $22.4, which is +139.06% compared to the current price. The earnings rating for Evelo Biosciences Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Evelo Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Evelo Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 24.51, ATR14 : 1.07, CCI20 : -210.81, Chaikin Money Flow : -0.36, MACD : -0.90, Money Flow Index : 23.43, ROC : -28.69, RSI : 31.42, STOCH (14,3) : 1.83, STOCH RSI : 0.00, UO : 34.93, Williams %R : -98.17), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Evelo Biosciences Inc. in the last 12-months were: David R. Epstein (Buy at a value of $85 466), Xiaoli Jacqueline Liu (Sold 3 000 shares of value $15 510 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (25.00 %)
2 (40.00 %)
2 (50.00 %)
Moderate Buy
0 (0.00 %)
1 (20.00 %)
1 (25.00 %)
Hold
3 (75.00 %)
2 (40.00 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.50
Moderate Buy
1.90
Moderate Buy
1.63

Evelo Biosciences Inc.

Evelo Biosciences Inc operates as a bio-technology company. It is an immuno-microbiome company, develops immunotherapies for the treatment of cancer, oncology, neuroinflammation, metabolism, autoimmune, and inflammatory diseases. The company develops therapies for the treatment of the gut-body network.

CEO: Balkrishan Gill

Telephone: +1 617 577-0300

Address: 620 Memorial Drive, Cambridge 02139, MA, US

Number of employees: 98

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

33%67%

Bearish Bullish

58%42%

Bearish Bullish

54%46%

News

Stocktwits